Skip to main content
Premium Trial:

Request an Annual Quote

Challenges and Collaboration

A biotech career can be challenging with the ups and downs of drug development and chasing approval for those therapies, FierceBiotech writes. Still, it adds, some people love a challenge.

It profiles 15 women in biotech "who have been doing some amazing things."

Shire's Susan Kilsby, for instance, engineered the $54.8 billion deal with AbbVie that gave shareholders £52.48 a share in cash and stock — more than AbbVie CEO Richard Gonzalez originally offered. Meanwhile, Cynthia Verst at Quintiles is growing that company's post-market study business by developing patient registries, examining outcomes data, and more.

Many of those profiled, FierceBiotech notes, attribute part of their success to working with their colleagues.

"There's nothing more powerful than having a team move toward something versus an individual," Eisai's Shaji Procida says. "Part of growing in your career is looking for moments of learning … so your breadth of experience can be wider when you grow into a leadership role."

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.